Dystrophin's isoforms are thought to contribute variably to neuropsychiatric disorders, behavioral disorders, and ...

Building empathy and having clear communication are key to improving patient outcomes in DMD, writes columnist.

Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...

Satellos Bioscience's experimental small-molecule drug for Duchenne muscular dystrophy is showing positive results as a stand-alone treatment, but Phil Lambert, Ph.D., the company's chief scientific ...

Cardiac complications in Duchenne muscular dystrophy (DMD) are the result of cardiac muscle involvement that accompanies the ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

It’s the world’s largest research-focused patient organization for one of the most prevalent forms of muscular dystrophy. The FSHD Society is working toward a cure to end the pain ...

The campaign to commemorate the work of the Muscular Dystrophy Association was created in partnership with agency Yes&.

In many genetic diseases, a small error in the DNA code can have devastating effects. These errors, called nonsense mutations ...

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further ...

Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a ...